Assays for prostate cancer : changing the screening paradigm?

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Serum prostate-specific antigen (PSA) testing has revolutionized prostate cancer (PCa) detection but leads to overdiagnosis and overtreatment.
• The need for more specific biomarkers is critical to improve PCa detection accuracy and patient management.
• Current PSA testing limitations necessitate the development of novel diagnostic tools.

Purpose of the Study:

• To provide an overview of novel blood- and urine-based biomarkers for prostate cancer detection.
• To explore biomarkers that can improve the identification of clinically significant PCa.
• To reduce the rate of unnecessary prostate biopsies through enhanced diagnostic specificity.

Main Methods:

• Systematic PubMed search conducted using MeSH terms: 'prostate cancer', 'biomarker', 'marker', and 'detection'.
• Literature review focused on English-language studies.
• Analysis of emerging blood- and urine-based biomarkers for PCa prediction.

Main Results:

• Several novel blood- and urine-based biomarkers demonstrate potential for improving PCa detection.
• These biomarkers may enhance the prediction of both the presence and significance of prostate cancer.
• Multivariate models combining multiple biomarkers show superior accuracy compared to single markers.

Conclusions:

• Novel biomarkers offer a promising avenue to optimize prostate cancer detection and diagnosis.
• The use of combined biomarkers in multivariate models can significantly improve the accuracy of identifying significant PCa.
• These advancements have the potential to reduce unnecessary invasive procedures like prostate biopsies.